...
首页> 外文期刊>Scientific reports. >Tissue and exosomal miRNA editing in Non-Small Cell Lung Cancer
【24h】

Tissue and exosomal miRNA editing in Non-Small Cell Lung Cancer

机译:非小细胞肺癌中的组织和外泌体miRNA编辑

获取原文
           

摘要

RNA editing in microRNAs has been recently proposed as a novel biomarker in cancer. Here, we investigated RNA editing by leveraging small-RNA sequencing data from 87 NSCLC (Non-Small Cell Lung Cancer) samples paired with normal lung tissues from The Cancer Genome Atlas (TCGA) combined with 26 plasma-derived exosome samples from an independent cohort. Using both the editing levels and microRNA editing expression, we detected deregulated microRNA editing events between NSCLC tumor and normal tissues. Interestingly, and for the first time, we also detected editing sites in the microRNA cargo of circulating exosomes, providing the potential to non-invasively discriminate between normal and tumor samples. Of note, miR-411-5p edited in position 5 was significantly dysregulated in tissues as well as in exosomes of NSCLC patients, suggesting a potential targetome shift relevant to lung cancer biology.
机译:MicroRNA中的RNA编辑已被提出为癌症中的新型生物标志物。在这里,我们通过利用来自87个NSCLC(非小细胞肺癌)样品的小RNA测序数据来研究RNA编辑与来自癌症基因组Atlas(TCGA)与癌症基因组(TCGA)合并的来自癌症基因组(TCGA),与来自独立队列的26个血浆衍生的外来样品。使用编辑水平和MicroRNA编辑表达式,我们在NSCLC肿瘤和正常组织之间检测到Derigated MicroRNA编辑事件。有趣的是,我们也首次检测到循环外泌体的MicroRNA货物中的编辑位点,从而提供了在正常和肿瘤样品之间非侵入性区分的潜力。值得注意的是,在组织中,在第5位中编辑的miR-411-5p在组织中以及NSCLC患者的外泌体中显着讨论,表明与肺癌生物学相关的潜在靶点转变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号